ADTL-EI1712 is an orally active, selective dual inhibitor of ERK1 and ERK5, exhibiting 93.54% and 89.35% inhibition against ERK1 and ERK5, respectively, at 1 μM; it induces regulated cell death—a form of cell death dependent on genetically encoded mechanisms—to overcome compensatory mechanisms in specific cancer cells both in vitro and in vivo.